GlassScriptPhysician profile
James L Seward
NPI 1326081142
$4,669.16
in general payments reported to CMS, 2019-2025
28 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $312 · 2021: $341 · 2022: $669 · 2023: $392 · 2024: $1,047 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.04 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $883.68 | 2019-2025 | Tremfya |
| Abbvie INC. | $667.60 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $439.85 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $406.98 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $366.23 | 2020-2025 | |
| Pfizer INC. | $237.33 | 2019-2025 | |
| Galderma Laboratories, L.P. | $199.40 | 2019-2024 | |
| Merz North America, INC. | $188.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $183.69 | 2019-2025 | Dupixent |
| Amgen INC. | $172.91 | 2019-2020 | |
| Allergan, INC. | $117.01 | 2019-2022 | |
| Leo Pharma INC. | $111.53 | 2021-2024 | Adbry |
| Ucb, INC. | $101.11 | 2019-2025 | Bimzelx |
| Tempus Ai, INC | $72.05 | 2024 | |
| Almirall LLC | $66.64 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $64.69 | 2024 | Daxxify |
| Lilly USA, LLC | $50.49 | 2020-2022 | |
| Incyte Corporation | $50.32 | 2022-2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $45.89 | 2022-2023 | Blu-U, Odomzo |
| Arcutis Biotherapeutics, INC. | $44.46 | 2023-2025 | Zoryve |
| Dermira, INC. | $42.90 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $34.65 | 2023 | |
| Botanix Sb INC | $23.48 | 2025 | Sofdra |
| Genentech USA, INC. | $22.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.68 | 2022 | |
| Biofrontera INC. | $21.64 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $20.49 | 2024 | |
| Epi Health, LLC | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Seward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.